Andreas Charidimou1, Jan O Friedrich2, Steven M Greenberg2, Anand Viswanathan2. 1. From the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada. andreas.charidimou.09@ucl.ac.uk. 2. From the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada.
Abstract
OBJECTIVE: To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA). METHODS: We systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (Aβ42, Aβ40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations: (1) in patients with CAA vs healthy controls and (2) in patients with CAA vs patients with AD. RoM >1 indicates higher biomarker concentration in patients with CAA vs comparison population and RoM <1 indicates higher concentration in comparison groups. RESULTS: Three studies met inclusion criteria. These comprised 5 CAA patient cohorts (n = 59 patients) vs healthy controls (n = 94 cases) and AD cohorts (n = 158). Three core biomarkers differentiated CAA from controls: CSF Aβ42 (RoM 0.49, 95% confidence interval [CI] 0.38-0.64, p < 0.003), Aβ40 (RoM 0.70, 95% CI 0.63-0.78, p < 0.0001), and t-tau (RoM 1.54, 95% CI 1.15-2.07, p = 0.004); p-tau was marginal (RoM 1.24, 95% CI 0.99-1.54, p = 0.062). Differentiation between CAA and AD was strong for CSF Aβ40 (RoM 0.76, 95% CI 0.69-0.83, p < 0.0001), but not Aβ42 (RoM 1.00; 95% CI 0.81-1.23, p = 0.970). For t-tau and p-tau, average CSF ratios in patients with CAA vs patients with AD were 0.63 (95% CI 0.54-0.74, p < 0.0001) and 0.60 (95% CI 0.50-0.71, p < 0.0001), respectively. CONCLUSION: Specific CSF patterns of Aβ42, Aβ40, t-tau, and p-tau might serve as molecular biomarkers of CAA, but analyses in larger CAA cohorts are needed.
OBJECTIVE: To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA). METHODS: We systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (Aβ42, Aβ40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations: (1) in patients with CAA vs healthy controls and (2) in patients with CAA vs patients with AD. RoM >1 indicates higher biomarker concentration in patients with CAA vs comparison population and RoM <1 indicates higher concentration in comparison groups. RESULTS: Three studies met inclusion criteria. These comprised 5 CAA patient cohorts (n = 59 patients) vs healthy controls (n = 94 cases) and AD cohorts (n = 158). Three core biomarkers differentiated CAA from controls: CSF Aβ42 (RoM 0.49, 95% confidence interval [CI] 0.38-0.64, p < 0.003), Aβ40 (RoM 0.70, 95% CI 0.63-0.78, p < 0.0001), and t-tau (RoM 1.54, 95% CI 1.15-2.07, p = 0.004); p-tau was marginal (RoM 1.24, 95% CI 0.99-1.54, p = 0.062). Differentiation between CAA and AD was strong for CSF Aβ40 (RoM 0.76, 95% CI 0.69-0.83, p < 0.0001), but not Aβ42 (RoM 1.00; 95% CI 0.81-1.23, p = 0.970). For t-tau and p-tau, average CSF ratios in patients with CAA vs patients with AD were 0.63 (95% CI 0.54-0.74, p < 0.0001) and 0.60 (95% CI 0.50-0.71, p < 0.0001), respectively. CONCLUSION: Specific CSF patterns of Aβ42, Aβ40, t-tau, and p-tau might serve as molecular biomarkers of CAA, but analyses in larger CAA cohorts are needed.
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Steven M Greenberg; R N Kaveer Nandigam; Pilar Delgado; Rebecca A Betensky; Jonathan Rosand; Anand Viswanathan; Matthew P Frosch; Eric E Smith Journal: Stroke Date: 2009-05-14 Impact factor: 7.914
Authors: Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg Journal: Lancet Neurol Date: 2016-04-08 Impact factor: 44.182
Authors: Dimitri Renard; Giovanni Castelnovo; Anne Wacongne; Anne Le Floch; Eric Thouvenot; Julie Mas; Audrey Gabelle; Pierre Labauge; Sylvain Lehmann Journal: J Neurol Date: 2012-05-11 Impact factor: 4.849
Authors: Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Ellis S van Etten; Marcel M Verbeek; Jeroen van der Grond; Ronald Zielman; Sanneke van Rooden; Erik W van Zwet; Anna M van Opstal; Joost Haan; Steven M Greenberg; Mark A van Buchem; Marieke J H Wermer; Gisela M Terwindt Journal: Neurology Date: 2016-11-30 Impact factor: 9.910
Authors: Steven M Greenberg; Rustam Al-Shahi Salman; Geert Jan Biessels; Mark van Buchem; Charlotte Cordonnier; Jin-Moo Lee; Joan Montaner; Julie A Schneider; Eric E Smith; Meike Vernooij; David J Werring Journal: Lancet Neurol Date: 2014-02-27 Impact factor: 44.182
Authors: Andreas Charidimou; Gregoire Boulouis; Matthew P Frosch; Jean-Claude Baron; Marco Pasi; Jean Francois Albucher; Gargi Banerjee; Carmen Barbato; Fabrice Bonneville; Sebastian Brandner; Lionel Calviere; François Caparros; Barbara Casolla; Charlotte Cordonnier; Marie-Bernadette Delisle; Vincent Deramecourt; Martin Dichgans; Elif Gokcal; Jochen Herms; Mar Hernandez-Guillamon; Hans Rolf Jäger; Zane Jaunmuktane; Jennifer Linn; Sergi Martinez-Ramirez; Elena Martínez-Sáez; Christian Mawrin; Joan Montaner; Solene Moulin; Jean-Marc Olivot; Fabrizio Piazza; Laurent Puy; Nicolas Raposo; Mark A Rodrigues; Sigrun Roeber; Jose Rafael Romero; Neshika Samarasekera; Julie A Schneider; Stefanie Schreiber; Frank Schreiber; Corentin Schwall; Colin Smith; Levente Szalardy; Pascale Varlet; Alain Viguier; Joanna M Wardlaw; Andrew Warren; Frank A Wollenweber; Marialuisa Zedde; Mark A van Buchem; M Edip Gurol; Anand Viswanathan; Rustam Al-Shahi Salman; Eric E Smith; David J Werring; Steven M Greenberg Journal: Lancet Neurol Date: 2022-08 Impact factor: 59.935
Authors: L Grangeon; G Quesney; X Ayrignac; D Wallon; M Verdalle-Cazes; S Coulette; D Renard; A Wacongne; T Allou; N Olivier; Y Boukriche; G Blanchet-Fourcade; P Labauge; C Arquizan; S Canaple; O Godefroy; O Martinaud; P Verdure; M Quillard-Muraine; J Pariente; E Magnin; G Nicolas; C Charbonnier; D Maltête; M Formaglio; N Raposo Journal: J Neurol Date: 2022-06-26 Impact factor: 6.682
Authors: Laura Gatti; Francesca Tinelli; Emma Scelzo; Francesco Arioli; Giuseppe Di Fede; Laura Obici; Leonardo Pantoni; Giorgio Giaccone; Paola Caroppo; Eugenio Agostino Parati; Anna Bersano Journal: Int J Mol Sci Date: 2020-05-13 Impact factor: 5.923
Authors: Gargi Banerjee; Gareth Ambler; Ashvini Keshavan; Ross W Paterson; Martha S Foiani; Jamie Toombs; Amanda Heslegrave; John C Dickson; Francesco Fraioli; Ashley M Groves; Michael P Lunn; Nick C Fox; Henrik Zetterberg; Jonathan M Schott; David J Werring Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472